Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
A phase 2 trial of rilzabrutinib in IgG4-related disease.
Journal: Annals of the rheumatic diseases
Published: February 03, 2026
Population Pharmacokinetic and Pharmacodynamic Modeling for the Prediction of the Extended Amlitelimab Phase 3 Dosing Regimen in Atopic Dermatitis.
Journal: CPT: pharmacometrics & systems pharmacology
Published: April 24, 2025
In Vitro Evidence Demonstrating the Nondepleting Mechanism of Action of Amlitelimab, an OX40 Ligand Monoclonal Antibody.
Journal: Acta dermato-venereologica
Published: April 11, 2025
Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis.
Journal: The Journal of allergy and clinical immunology
Published: July 26, 2024
The Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular Dystrophy.
Journal: Neurology and therapy
Published: September 11, 2023
Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized Study.
Journal: The Journal of investigative dermatology
Published: August 14, 2023
Stride Velocity 95th Centile: Insights into Gaining Regulatory Qualification of the First Wearable-Derived Digital Endpoint for use in Duchenne Muscular Dystrophy Trials.
Journal: Journal of neuromuscular diseases
Published: December 27, 2021
Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE).
Journal: Journal of the American Academy of Dermatology
Published: November 06, 2017
Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation.
Journal: American journal of respiratory and critical care medicine
Published: April 18, 2013
Last Updated: 09/26/2026